Podcasts about zebras

Dr. Yanina Pasikhova, Infectious Diseases Pharmacist at Moffitt Cancer Center and Research Institute, presents a talk on three lesser well known adverse drug effects involving antimicrobials. Dr. Pasikhova discusses the link between voriconazole and bone pain, the association between posaconazole and refractory hypertension and hypokalemia, and the neurological effects of of metronidazole therapy. Clinical pearls are provided for each interaction discussed.

In this episode of The Big Table Podcast I sit down with Colby Jubenville: a human performance expert, professor, trusted advisor, and co-author of Zebras and Cheetahs for one of the deepest conversations we've had on leadership, identity, burnout, culture, and what really causes people and teams to fail.Colby breaks down the psychology behind bad leadership, why high performers sometimes become toxic, and how unresolved tension destroys organizations from the inside out. We discuss accountability, trust, questions-based leadership, emotional exhaustion, team dysfunction, and why most leaders avoid the hard conversations that actually create growth.We also revisit lessons from our book Zebras and Cheetahs and reflect on over a decade of working together in the business world — from staying in cheap hotels and building consulting businesses to helping leaders scale teams, develop culture, and navigate adversity under pressure.If you're an entrepreneur, leader, coach, executive, athlete, or someone trying to unlock higher performance in life and business, this conversation will challenge the way you think about leadership and human behavior.Chapters:00:00 - Dr. Jubenville02:30 - Zebras and Cheetahs03:50 - How To Stop Workplace Drama06:50 -Toxic High Performers08:31 - The Dysfunction and The Dance13:45 - Asking Questions18:38 - The Big Table19:22 - The Low Hanging Fruit23:30 - Trusted Advisor30:30 - Battle Testing36:45 - People Focus On The Negative40:30 - Zebras and Cheetahs Revisited41:10 - How Did We Get Here43:40 - Like and Subscribe!________________________________Get connected with Coach Burt:Instagram - https://www.instagram.com/michealburtTikTok - https://www.tiktok.com/@therealcoachburtFacebook - https://www.facebook.com/CoachMichealBurtLinkedIn - https://www.linkedin.com/in/michealburtDive deeper with Coach and his concepts:Free PreyDrive Planner: https://planner.coachburt.com/plannerEvents: https://www.thegreatnessfactory.com/eventsJoin Our Group Coaching: https://www.thegreatnessfactory.com/membershipHire Me To Speak: https://www.coachburt.com/bookcoachCheck Out My Books: https://books.coachburt.com/books

Virgio Šidlausko pasakas „Geraširdis ryklys“, „Piranija, kuriai iškrito dantis“ ir „Zebras, norėjęs išgelbėti pėsčiųjų perėją“ skaito aktorius Giedrius Arbačiauskas.

See omnystudio.com/listener for privacy information.

Neste episódio, Denis Botana e Danilo Silvestre falam sobre os Jogos 2 das oito séries de Playoffs da NBA. Quem respondeu bem ao domínio dos mandantes nas estreias e quem se mostrou maior candidato a zebra nessa primeira fase. Durante os PLAYOFFS 2026 o Bola Presa terá duas edições por semana, às segundas e às quintas....NESTE EPISÓDIOIntrodução - 0:40Carinha do Jabá - 1:28 Cavs x Raptors - 3:33Knicks x Hawks - 11:30Nuggets x Wolves - 22:44Celtics x Sixers - 38:20Sharke Investimentos -49:20Spurs x Blazers - 52:28Lakers x Rockets - 1:08:47Pistons x Magic - 1:20:27Thunder x Suns - 1:26:32...|OS PARÇAS DO BOLA PRESA|ASSINE O BOLA PRESA E RECEBA CONTEÚDO EXCLUSIVO Por R$30 por mês você tem grupo no zap, bingo e mais de 100 podcasts exclusivos extras .CAMISETAS INSIDER Com nosso cupom BOLAPRESA você tem 15% OFF, já aplicado automático se usar o link abaixo:

Brooke Dillman and first-timer Brian Gattas join Tony, Daniel and me to talk about the dazzle of zebras Brooke saw, Brooke's amazing performance as friend-of-the-show Jeff Drake, how Gattas knows everyone, Tony's harrowing Coachella weekend, S'Mores, bunk bed dangers, The Olympics, a fish update and more. Plus we did a round of JMOE, HGFY and Podcast Pals Product Picks. Get yourself some new ARIYNBF merch here: https://alison-rosen-shop.fourthwall.com/ Subscribe to my Substack: http://alisonrosen.substack.com Podcast Palz Product Picks: https://www.amazon.com/shop/alisonrosen/list/2CS1QRYTRP6ER?ref_=cm_sw_r_cp_ud_aipsflist_aipsfalisonrosen_0K0AJFYP84PF1Z61QW2H Products I Use/Recommend/Love: http://amazon.com/shop/alisonrosen Check us out on Patreon: http://patreon.com/alisonrosen   This episode is brought to you by: SHOPIFY (shopify.com/alisonrosen) MINT MOBILE (mintmobile.com/alisonrosen) WAYFAIR (wayfair.com) This episode is brought to you by FACTOR. (Use code alisonrosen50off for 50 percent off and free breakfast for a year) Buy Alison's Fifth Anniversary Edition Book (with new material): Tropical Attire Encouraged (and Other Phrases That Scare Me) https://amzn.to/2JuOqcd You probably need to buy the HGFY ringtone! https://www.alisonrosen.com/store/ Try Amazon Prime Free 30 Day Trial

KERRI ZANEAI Innovation: Kerri Zane's Creative Career JourneySummaryIn this engaging interview, Kerri Zane shares her extensive experience in reality TV, her innovative ventures into AI in media, and invaluable advice for aspiring producers and storytellers. Discover how she navigates the evolving landscape of entertainment, the role of AI, and tips for success in the industry.Sound Bites"Never give up. I never stop. I never give up.""When someone says no to me, that's when I get started."ChaptersSetting the Stage: Introduction and BackgroundEmbracing AI in Media: A New EraThe Art of Production: Roles and ResponsibilitiesReality TV: Crafting Stories and ConflictNavigating the Pitch Process: Tips for SuccessThe Evolution of Content Creation: From Traditional to AIThe Importance of Human Creativity in AIAdvice for Aspiring Creatives: Never Give UpBooks and Personal Growth: Sharing ExperiencesClosing Thoughts: The Future of StorytellingHow women are rewriting the rules—no apologies neededDrop a

The biggest storylines going into The Masters is...then the Male Sack is bursting at the seams...and are Zebras considered fast?

Auch an Ostern versteckt sich keiner der 4zu3-Crew vor der Nachbesprechung des Drittligawochendes, an dem vor allem das Derby zwischen Essen und Duisburg im Mittelpunkt stand. Während RWE als Sieger der 2. Liga ein Stückchen nähergekommen ist, hadern die Zebras mit der Pleite. MSV-Spieler Can Coskun erklärt die Gründe für die Derbyniederlage und blickt auf den Rest der Saison. Und falls ihr uns Sprachnachrichten zukommen lassen wollt, könnt ihr das gerne unter folgender Nummer tun: 0151 566 58 335

In this episode we set the Elevator of History back to 1835 where we witness the ;'penny paperss' papers sold for one cent instead of six that featured stories people WANTED to read, rather than news by and for a political party.  These papers brought us separate sections on news, finance, sports and featured on the scene reporting and lurid true crime details.  But it was the New York Sun that launched into a six day report of what a famous mathematician, chemist and learned individual was looking at the moon through a legendary telescope and reporting the discovery of the most amazing things including:  albino moon-bison, miniature zebras, one horned goats, unicorns and the fascinating bat people of the moon who dwelt in massive temples carved from giant rubies.  The public was fascinated by this series of articles until the report, six days later that the telescope had caught a stray sunbeam, magnified it's intensity and set the observatory alight causing it to burn to the ground.  In the days and weeks that followed it slowly came out that none of this was true, however, the Sun never printed a retraction and their readership had grown significantly despite the scandal, most new readers stayed.  We discuss all this, the Blue Fugates, touch on Orson Welles War of the Worlds  and discuss Terry Gilliam's the Adventures of Baron Munchausen  in this it can't get weirder than this episode of the Family Plot Podcast!Become a supporter of this podcast: https://www.spreaker.com/podcast/family-plot--4670465/support.

Follow, Like, Comment & Subscribe! #dayones Discount Codes Here: linktr.ee/latenitewnate​ Another week where we discuss the latest mess like Zebras, Monica and so much more! Give it a listen and tell us what you think!

What's SHE Up To Now Day 2973? Start NOW, Supersize Challenges, Zebras, Family And Skool Community! Pop here every day for a dose of different business building perspective: https://facebook.com/supersizebusiness #supersizeyourbusiness #supersizyouuchallenge #supersizeyourbusinessannualchallenge #supersizeyourbusinesschallenge #moneymonth #documentthejourney #financialhealth #givevalue #skoolcommunity #zebras #investnow #timeisnow #timing

What an AMAZING lesson, Podcast Family, in this impromptu episode, we will hear from one of my former medical students, now BOARD-CERTIFIED OBGYN...and an incredible OB case she just had. Sometimes....we find ZEBRAS! Great job, Lauren!

Hunde, Katzen und Kühe wurden domestiziert – Zebras, Füchse und Elche dagegen nicht. Die Gründe dafür sind überraschend komplex und zeigen, wie außergewöhnlich es ist, dass sich Tiere dem Menschen überhaupt anschließen. Über die Regeln der Domestikation spricht Andreas Albes mit P.M.-Autor Thomas Wagner. +++ Wenn ihr Fragen habt, die wir für euch beantworten sollen, dann schreibt uns an: pm-redaktion@verlagshaus.de +++ Lust auf mehr Wissenschaft? Hier geht's zum günstigen P.M.-Testabo: https://www.verlagshaus24.com/p_m__zum_testen-vz-web-p.m.-17180-gb-mex/?utm_source=website&utm_medium=digital&utm_campaign=pmm-testabo +++ Weitere Infos zu unseren Werbepartnern finden Sie hier: https://linktr.ee/schnellerschlau +++ https://www.rtl.de/cms/service/footer-navigation/impressum.html +++ Dieser Podcast wird vermarktet von Julep Media: sales@julep.de

Joshua Resnikoff was a bench scientist at Harvard's Wyss Institute, surrounded by cutting-edge science. He believed healthcare could solve anything. Then his son started having unexplained recurring fevers. Monthly ER visits. Ice baths to prevent seizures. Years of diagnostic uncertainty. Finally, a diagnosis: PFAPA, a hyper-inflammatory condition so rare only 500 kids in the US have it. The doctor's response? "There's nothing we can do. It's not terminal, so don't worry about it."That was his red pill moment.On this episode of Ditch the Labcoat, Dr. Mark Bonta sits down with Joshua, founder and CEO of Sunstone Health, to explore what happens when families get trapped in the diagnostic odyssey. Joshua built a platform that compresses a seven-year diagnostic journey into 12 weeks by using AI to find hidden rare disease patients buried in insurance claims data.Dr. Bonta and Joshua tackle the hard questions: What happens when doctors don't know what's wrong? Why does the healthcare system fail zebra patients while teaching doctors to only look for horses? And what role does physician attitude play in solving diagnostic mysteries?If you've ever felt dismissed by the healthcare system or wondered whether AI can actually help real patients, this conversation will challenge everything you thought you knew about precision medicine and patient advocacy.Joshua Resnikoff's Website : https://www.sunstonehealth.com/Episode Takeaways1. The diagnostic odyssey for rare diseases averages 7 years—Sunstone compresses it to 12 weeks using AI and insurance claims data.2. "There's nothing we can do" isn't medical reality—it's often a failure of attitude, not knowledge or skills.3. Rare disease families are desperate for answers, making them vulnerable to predatory experimental treatments and unproven therapies.4. Health plans, not patients, are Sunstone's customers—financial incentives align when undiagnosed kids cost insurers millions in repeated ER visits.5. Doctors are taught "when you hear hoofbeats, think horses not zebras"—but 2% of hospital patients are zebras with no diagnosis after 24 hours.6. Genetic testing isn't just about diagnosis—it's about getting specialty guidance back to local doctors so families don't travel hours for care.7. Patient data ownership matters—families should control their genetic reports and medical records, not insurance companies.8. Expanding from genetic epilepsy into autism, familial hypercholesterolemia, and other rare diseases—the goal is to be infrastructure for all non-oncology genetic disease.Episode Timestamps04:11 – The Red Pill Moment: "There's Nothing We Can Do"07:07 – Building Community: From Desperation to Action11:42 – How Sunstone Works: Finding Hidden Patients in Claims Data19:22 – Seven Years to 12 Weeks: Compressing the Diagnostic Odyssey25:17 – Zebras vs. Horses: When Rare Disease Becomes Your Reality33:46 – The Attitude Problem: Why Doctors Give Up on Diagnostic Mysteries37:48 – Medical Desperation: Experimental Treatments and Predatory Care45:38 – The Future: Expanding Beyond Epilepsy into Autism and BeyondDISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.    Disclosures: Ditch The Lab Coat podcast is produced by (soundsdebatable.com) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. 

Troubleshooting lighting systems isn't just about knowing the technology—it's about thinking clearly under pressure. In this episode of the Lighting Controls Podcast, industry veteran David Fox shares powerful real-world insights from nearly three decades in entertainment and architectural lighting. From separating symptoms vs. real problems to asking smarter questions and staying calm when everything is on fire, David breaks down the soft skills and mindset that make great troubleshooters. This conversation features practical strategies to diagnose issues faster, communicate better, and solve problems without losing your head.Key takeaways:Why troubleshooting is more about process than product knowledge How to identify the actual problem behind the symptoms The importance of clear communication and active listening Simple techniques like divide-and-conquer debugging Why the best technicians know where to find answers, not just the answers themselves A must-listen for technicians, integrators, and anyone who's ever heard the words:“The lights aren't working.”

How many animals can you think of that are black and white? Zebras, penguins, orcas, snow leopards… there are loads! But have you ever wondered why these animals have developed such unique and striking appearances? Neil and Becca discuss this and teach you some new vocabulary.As always, find a free transcript, worksheet and quiz for this episode on our website: ✔️ https://www.bbc.co.uk/learningenglish/english/features/6-minute-english_2026/ep-260305And find NEW episodes of Office English here or by searching 'Learning English for Work' on your favourite podcast app: ✔️ https://www.bbc.co.uk/learningenglish/english/features/office-englishSubscribe to our newsletter to receive our weekly highlights in your inbox: ✔️ https://www.bbc.co.uk/send/u178220599Other podcasts you might enjoy: ✔️ Learning English Grammar ✔️ Learning English from the News ✔️ Learning English Stories

Am 29. Februar, dem seltensten Tag im Kalender, ist der offizielle Rare Disease Day. In Nicht-Schaltjahren - wie 2026 - findet er am 28. Februar statt. Rund um den Globus finden dann Aktionen statt, die die Sichtbarkeit von seltenen Erkrankungen erhöhen und Solidarität mit den Betroffenen zeigen. Auch Martin und Daniel feiern den besonderen Tag in dieser Episode, die vollgepackt ist mit Updates aus Forschung, Neuigkeiten aus Medizin und handfesten Tipps, wie auch ihr eine Beitrag zum diesjährigen Rare Disease Day leisten könnt

Why Zebras Don't Get Ulcers—But We Do Ever wondered why zebras can outrun lions without breaking a sweat, while humans get ulcers just thinking about Monday? Join biochemist Phil George as he dives into the wild world of stress biology in this eye-opening episode: Discover: How evolution shaped our stress response Why chronic anxiety is a modern epidemic What zebras can teach us about resilience and recovery Whether you're a science nerd, a burnout survivor, or just zebra-curious, this episode will change how you think about your body, your brain, and your daily grind. Available now wherever you get your podcasts. Tap in, chill out, and get ready to rethink stress. Available now on all podcast platforms. Please feel free to email Phil at philgeorge@charter.net with any health/nutrition/exercise questions. https://www.wellnesswave.net/

Harden, SGA, Avdija? Is he a free throw merchant?

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Ben Maller talks about the Seattle Seahawks defeating the Rams on TNF thanks to a controversial call from the officials, how concerned Sean McVay should be after the Rams loss, if Sam Darnold saved himself with that crazy comeback win, if this kills the Stafford MVP campaign, and more!See omnystudio.com/listener for privacy information.

Have you ever wanted a bed for your phone? Do you live in the United Arab Emirates? Well, you're in luck. Ikea has the perfect thing for you. We discuss Nike's latest product that makes it easier to walk for people who were not having trouble walking (??). We created the perfect foot race, and it involves flip-flops, margaritas, and fun for the whole family. This might be our best idea yet. We learn why horses got domesticated and zebras didn't, and we also realize zebras are the reality tv personaliteis of the animal kingdom (in the worst way). We find out why octopuses are more similar to humans than we realized, except for how they might be aliens. Plus, we discuss a boy who was kidnapped that was released because he annoyed the hell out of his captors, and we stan.Brain Candy Podcast Website - https://thebraincandypodcast.com/Brain Candy Podcast Book Recommendations - https://thebraincandypodcast.com/books/Brain Candy Podcast Merchandise - https://thebraincandypodcast.com/candy-store/Brain Candy Podcast Candy Club - https://thebraincandypodcast.com/product/candy-club/Brain Candy Podcast Sponsor Codes - https://thebraincandypodcast.com/support-us/Brain Candy Podcast Social Media & Platforms:Brain Candy Podcast LIVE Interactive Trivia Nights - https://www.youtube.com/@BrainCandyPodcast/streamsBrain Candy Podcast Instagram: https://www.instagram.com/braincandypodcastHost Susie Meister Instagram: https://www.instagram.com/susiemeisterHost Sarah Rice Instagram: https://www.instagram.com/imsarahriceBrain Candy Podcast on X: https://www.x.com/braincandypodBrain Candy Podcast Patreon: https://www.patreon.com/braincandy (JOIN FREE - TONS OF REALITY TV CONTENT)Brain Candy Podcast Sponsors, partnerships, & Products that we love:For a limited time, get 60% off your first order, plus free shipping, when you head to https://www.smalls.com/BRAINCANDYGet 15% off OneSkin with the code BRAINCANDY at https://www.oneskin.co/BRAINCANDY #oneskinpodHead to https://cozyearth.com and use my code BRAINCANDY for up to 40% off — just be sure to place your order by December 12th for guaranteed Christmas delivery. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

🧭 REBEL Rundown 📝 Introduction Welcome to the Rebel Core Content Blog, where we delve into crucial knowledge for emergency medicine. Today, we share insightful tips from PEM specialist Dr. Elise Perelman, shedding light on respiratory challenges in infants, toddlers, and young children during the viral season. Understanding that most cases involve typical viruses, we aim to equip you with diagnostic pearls to identify more serious pathologies. Click here for Direct Download of the Podcast. 🔍 Recognizing Respiratory Patterns Pearl #1: Look at Your PatientBegin exams from the doorway. Observing patterns such as accessory muscle usage can reveal a patient’s respiratory effort. Specify whether the work of breathing occurs during inspiration, expiration, or both. Inspiratory work indicates difficulty getting air in, while expiratory work suggests trouble pushing air out. Silent tachypnea may point to other issues, like acidemia or pneumothorax. 🩺 Localizing Sounds for Accurate Diagnosis Pearl #2: Localize the SoundBreathing noises signal varied respiratory issues. Stridor, often heard on inspiration, results from obstructions above the thoracic inlet. Conversely, wheezing, generally linked to exhalation, indicates obstructions in the lower airways. Watch for signs like ‘silent chest’—a dangerous, severe obstruction, and distinguish grunting as a bodily mechanism to prevent alveolar collapse. Correctly identifying the sound assists in determining the appropriate intervention. 💉 Tailoring Treatment for Effective Results Once a sound is localized, treatments vary. We explore Soder from nasal congestion, typically needing supportive care and suctioning. Stridor from conditions like croup is eased with interventions to reduce airway swelling, such as steroids or inhaled epinephrine. Conversely, wheezing in infants is often due to bronchiolitis—not bronchospasms—and over-treatment is to be avoided. Supportive measures including suction, hydration, and oxygen are preferred unless improvement warrants bronchodilators. 🌬️ Intervening with Severe Asthma In severe cases of asthma or bronchiolitis, where standard at-home treatments fail, immediate adjunct therapies like intramuscular epinephrine become essential. Administering this quickly can alleviate obstruction when inhalants aren’t effective due to low air movement. 🦓 Navigating the Zebras of Respiratory Cases When recognizing Zebras—uncommon cases overshadowed by routine diagnoses—remain vigilant for histories or presentations that don’t conform. Conditions like pneumonia, bacterial tracheitis, and even myocarditis may mimic more common issues. 📌 Conclusion As attending physicians, our role extends beyond conventional treatment—it’s about discerning the atypical from the typical. Dr. Perelman urges continual reassessment, emphasizing reliance on observational skills as much as technological aid. Keeping keen on respiratory nuances ensures we catch those outlier cases, paving the way for adept medical care despite the overwhelming prevalence of viral infections.Stay tuned for more pearls and insights in our future posts, as Dr. Perelman shares further strategies for effective pediatric emergency care. For more resources, continue exploring our faculty’s valuable contributions on our site. Until then, stay safe and perceptive in your practice. Post Peer Reviewed By: Mark Ramzy, DO (X: @MRamzyDO), and Marco Propersi, DO (X: @Marco_Propersi) 👤 Guest Elise Perlman MD Pediatric Emergency Medicine​ Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Meet The Team 🔎 Your Deep-Dive Starts Here REBEL Core Cast – Pediatric Respiratory Emergencies: Beyond Viral Season Welcome to the Rebel Core Content Blog, where we delve ... Pediatrics Read More REBEL CAST – IncrEMentuM26 Speaker Spotlight : Drs. Tarlan Hedayati, Jess Mason and Simon Carley Host Dr. Mark Ramzy shines a spotlight on three distinguished ... Resuscitation Read More REBEL Core Cast 145.0: Understanding QTc Prolongation: Causes, Risks, and Management The QT interval is a vital part of ECG interpretation, ... Procedures and Skills Read More REBEL Core Cast 144.0: Tourniquet Tips In this episode of the Rebel Core Content podcast, Swami ... Procedures and Skills Read More REBEL CAST – IncrEMentuM26 Speaker Spotlight : George Willis and Mark Ramzy 🧭 REBEL Rundown 📝Introduction In this exciting episode of REBEL ... Endocrine, Metabolic, Fluid, and Electrolytes Read More REBEL Core Cast – DKA: Beyond the Basics Part 2 – SCOPE DKA-Trial Managing diabetic ketoacidosis (DKA) requires careful consideration of fluid therapy, ... Endocrine, Metabolic, Fluid, and Electrolytes Read More The post REBEL Core Cast – Pediatric Respiratory Emergencies: Beyond Viral Season appeared first on REBEL EM - Emergency Medicine Blog.

HITM: Today we do our annual check in and baby Zebra count with our friend Dominique Ferraro of Zebras R Us. Learn about Ozone from Jamie's vet and a tribute to Jane Goodall and more random horsey stuff! Listen in…AUDITOR POST SHOW: We discuss the auditor's answers to the question….if you could have dinner with anyone dead or alive who would it be? HORSES IN THE MORNING Episode 3825 – Show Notes and Links:Hosts: Jamie Jennings of Flyover Farm and Glenn the GeekJamie and Glenn's Amazon StoreEnter to win Holiday Week PrizesGuest: Dominique Ferraro of Zebras R Us - Buy merch hereGuest: Dr. Kimberly Rasmussen of Redbud Equine Veterinary ClinicAdditional support for this podcast provided by: US Rider, Equestrian +, Equine Network and Listeners Like YouTime Stamps: 01:00 - Jane Goodall tribute07:00 - Daily Whinnies08:00 - Losing Duke21:18 - Dominique Ferraro37:02 - Dr. Kimberly Rasmussen

HITM: Today we do our annual check in and baby Zebra count with our friend Dominique Ferraro of Zebras R Us. Learn about Ozone from Jamie's vet and a tribute to Jane Goodall and more random horsey stuff! Listen in…AUDITOR POST SHOW: We discuss the auditor's answers to the question….if you could have dinner with anyone dead or alive who would it be? HORSES IN THE MORNING Episode 3825 – Show Notes and Links:Hosts: Jamie Jennings of Flyover Farm and Glenn the GeekJamie and Glenn's Amazon StoreEnter to win Holiday Week PrizesGuest: Dominique Ferraro of Zebras R Us - Buy merch hereGuest: Dr. Kimberly Rasmussen of Redbud Equine Veterinary ClinicAdditional support for this podcast provided by: US Rider, Equestrian +, Equine Network and Listeners Like YouTime Stamps: 01:00 - Jane Goodall tribute07:00 - Daily Whinnies08:00 - Losing Duke21:18 - Dominique Ferraro37:02 - Dr. Kimberly Rasmussen

Are any people particularly susceptible to alopecia-linked hair loss? Also, what causes eczema and why does it keep recurring, why are the progeny of different species infertile, why does hair go grey but not always symmetrically, and Is asthma a risk factor for bronchitis? Plus, are zebras actually black with white stripes, or white with black stripes?! Join Dr Chris Smith and Clarence Ford to Ask the Naked Scientist... Like this podcast? Please help us by supporting the Naked Scientists

Are any people particularly susceptible to alopecia-linked hair loss? Also, what causes eczema and why does it keep recurring, why are the progeny of different species infertile, why does hair go grey but not always symmetrically, and Is asthma a risk factor for bronchitis? Plus, are zebras actually black with white stripes, or white with black stripes?! Join Dr Chris Smith and Clarence Ford to Ask the Naked Scientist... Like this podcast? Please help us by supporting the Naked Scientists

Join Dr. Shine on What's Your Shine? The Happy Podcast for a wildly fun and surprisingly meaningful conversation with Billy & Tiffany Roussel — the couple who dated their way through the alphabet. Yes, the alphabet. Twenty-six letters. Twenty-six dates. From "A is for Antipasto" all the way to "Z is for Zebras in Denmark." In this episode, Billy and Tiffany share how a simple idea — choose a letter and plan a surprise date around it — turned into a two-year experiment in presence, creativity, and choosing each other on purpose. What starts as a playful challenge becomes something deeper: a journey into vulnerability, partnership, and rediscovering the joy of making memories. Listeners will hear behind-the-scenes stories of their most outrageous dates, their funniest mishaps, and the unexpected emotional growth that came from stretching beyond comfort zones. Tiffany reveals what it was like to perform a literal interpretive dance as her reveal for the letter "I", while Billy opens up about what it took to plan experiences with meaning instead of simply checking a box. They didn't just finish the alphabet — they finished different. Different as individuals, and different as a couple. This episode is proof that intentionality fuels connection, that curiosity makes room for delight, and that love grows when you create opportunities to see each other with fresh eyes. Key Takeaways: How Alphabet Dating reignited creativity in their relationship Why shared experiences build deeper emotional bonds than routine "dinner and a movie" dates Simple steps to start your own version of Alphabet Dating What happens when you consistently choose surprise, adventure, and joy By the end, you'll be asking yourself: If love is spelled with action, what letter will you start with? Hit play — and get ready to be inspired to date differently.

Nick and Joseph recap week 8 of the NFL season.

Send us a textNorthern California, this stretch sand, rocks, logging roads, wineries, tiny towns and pulsing centers of culture are one of my happy places. Often when I travel here to visit family, I fly into Santa Rosa, a quaint airport that feels like a time capsule, with touches of Peanuts' cartoonist, Charles Schultz everywhere. Fog-nipped mornings, the sound of a distant train, a winding stretch of trees, shoulders of highway that drop off a rocky incline, this is a place best enjoyed like a glass of fine wine, one intentional sip at a time.From a lost bit of coastline to a community that has its own dialect that's about to go extinct, which might not be a bad thing, there's lots to learn about and love in Northern California.Let's get into it!This episode covers The Lost Coast, B. Bryan Preserve, Bohemian Grove, Zodiac, Mount Shasta, Boontling, and more.What to Watch, Listen to, Read, or Shop for NEXT!CASCADIA episode on Mount Shasta, Buzzsprout (shout out to Hotes Design - that created the episode art!) Exploring California's Lost Coast, VisitCalifornia.com B. Bryan Preserve link to donate, book a tour, fall in love with a giraffe, or plan an overnight stay!Want a Spiffy House? Acreage by the Pacific? Zebras? Here's the House for You, SF Gate Earth's Root Chakra: the mysticism of Mount Shasta, Backcountry MagazineStrange, Unique Northern California, CaliforniaThroughMyLense.comCalifornia - A List of the Weirdest Things to Ever Happen in Northern California, OnlyInYourState.com11 Weird Facts about Northern California that Sound FAKE but are 100% TRUE, Only In Your StateI don't accept sponsors and paid advertisers. I choose people, podcasts and authors I believe in to highlight in the ad segment. That's why I've been shining a spotlight on Derek Condit at Mystical Wares. He is both talented and generous with those gifts. Please give his books a look on the Mystical Wares website.Curious Cat Crew on Socials:Curious Cat on Twitter (X)Curious Cat on InstagramCurious Cat on TikTokArt Director, Nora, has a handmade, ethically-sourced jewelry company!

Program Staff Adam Borneman and Jennifer Watley Maxell talk to Avril Speaks and Julie Tiemann about the concept of actionable hope, the importance of focusing on the Divine, and how all the information we absorb without narrative ends up disconnecting us.

Avion was a healthy and athletic 15-year-old who became critically ill when he was admitted into a pediatric intensive care unit. For Robin Williams, assistant professor of pediatric hematology/oncology at the University of Minnesota Masonic Children's Hospital, Avion offered a medical puzzle she couldn't crack on her own. His immune system was on overdrive and it was attacking healthy cells and organs within his body. Though testing ruled out blood cancers, it was only when Williams consulted a friend outside the hospital that she realized Avion was suffering from TAFRO, a subtype of the ultra-rare disorder idiopathic multicentric Castleman's disease, a condition that has characteristics of both blood cancers and autoimmune disease. We spoke to Williams about the challenges physicians face in diagnosing patients with rare diseases, the thought process she went through in Avion's case, and why she's working to educate other physicians about the ultra-rare condition.

The Kongversation Divides its time between Sublayer 400 and the Freezer Layer of Donkey Kong Bananza! And since there's a Freezer Layer, we had to have Freezer on as the co-host for this episode to figure out if the Zebras are getting milked and if DK is impressed with his horsey Bananza endowment! Note: This episode only contains spoilers through the end of Sublayer 503.

On this week's solo ep, Cat and Pat catch up as Cat is performing in Edinburgh and Pat is writing away in Los Angeles. They talk about the feeling of wasting your morning, loving folklore, touch base on their favorite shapes, and have an enlightening discussion on the perfect duration of a massage. Watch the full episode on our YouTube and follow below!Show Instagram: https://www.instagram.com/seektreatmentpodShow Tiktok: https://www.tiktok.com/@seektreatmentpodCat: https://www.instagram.com/catccohenPat: https://www.instagram.com/patreegsSeek Treatment is a production of Headgum Studios. Our producer is Allie Kahan. Our executive producer is Emma Foley. The show is engineered and edited by Richelle Chen. The show art was created by Carly Jean Andrews. Like the show? Rate Seek Treatment on Spotify and Apple Podcasts and leave a review.Advertise on Seek Treatment via Gumball.fmSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nicholas Sloan is a Wisconsin-based Network Engineer, a dad of 4, and an extremely motivated chess improver. Usually. But after an incredible run of gaining 500+ rating points in two years, fueled by consistent hard work and a unique study approach, Nick hit a wall. He gave back 150 rating points, and lost his motivation to work hard on chess. That can happen when you are a family man who is working full-time,  studying for multiple hours a day, and creating chess content on top of that. Nick took time away to read some quality chess books, and to recalibrate his chess improvement plans. In our conversation Nick tells me:  Why, after reflection,  he has decided that the lofty goal of earning the National Master title is still worth pursuing.  How a few chess books opened his eyes to the work he still had to do  What he intends to do next As a longtime reader of Nick's blog, I was excited to finally chat with him, and I look forward to following his continued success.  Thanks to our sponsor, Chessable.com! If you sign up for Chessable Pro in order to unlock discounts and additional features, be sure to use the following link: https://www.chessable.com/pro/?utm_source=affiliate&utm_medium=benjohnson&utm_campaign=pro And you can check out their new offerings here: https://www.chessable.com/courses/all/new/ https://www.perpetualchesspod.com/partners 02:00- Nicholas joins the show- check out his rating graph here: https://www.uschess.org/datapage/ratings_graph.php?memid=12772484 05:00- What does Nick think contributed to his recent slump? 14:00- What effect did reading GM Jonathan Rowson's books have on Nick? Mentioned: Book Recap #14: Seven Deadly Chess Sins https://www.perpetualchesspod.com/new-blog/2021/1/29/book-recap-the-seven-deadly-chess-sins Book Recap #32: Chess for Zebras  https://www.perpetualchesspod.com/new-blog/2021/1/29/book-recap-the-seven-deadly-chess-sins 20:00- More book recs! Mentioned: Road to Chess Improvement Chess Improvement: It's All in the Mindset 22:00- How did Nick adjust to being an emotional player? 24:00- How has Nick changed his approach? Mentioned: Pump Up Your Rating  27:00- What thought process is Nick using over the board? Mentioned: GM Alexander Goldin  28:00- What did Nick learn from the book Rapid Chess Improvement ? Mentioned: CT-Art , Chessking App 32:00- How Nick avoids burnout Mentioned: Episode 173 with NM Philemon Thomas, GM Johan Hellsten's Mastering Chess Strategy 35:00- Why does Nick focus on local club tournaments rather than big weekend ones? Mentioned: Episode 346 with NM Todd Bryant  40:00- Does Nick play a narrow or wide repertoire?  44:00- How many tournament games does Nick aim to play per year?  46:00- Nick's approach to game analysis  50:00- Thanks to Nick for joining! Here is his linktree that provides many ways to keep up with him: https://linktr.ee/HighgroundChess If you would like to join the Perpetual Chess Patreon community, you can do so here: https://www.patreon.com/c/perpetualchess Check out special offers for free trials and/or discounts from our partner websites including Chessmood, ChessDojo, and Chess.com via the link below: Learn more about your ad choices. Visit podcastchoices.com/adchoices

Listen, Like and Subscribe on Apple or Spotify Podcasts: Brian Boero, co-founder and CEO of 1000Watt, joins Kevin Oakley for a punchy, high-frequency conversation on how home builders can (and should) learn from the broader real estate world. With decades of insight from both agents and consumers, Brian brings a unique lens to current challenges – and opportunities – for builders navigating 2025's volatile market.

This episode previews Brian's upcoming talk at the Online Sales & Marketing Summit, pulling from his research, fieldwork, and no-BS branding instincts to spark fresh perspective on how to break from the herd, build trust with brokers, and tap into what today's buyers actually want.Break the Pattern Before It Breaks You• Builders that mimic competitors become the slowest zebra• A standout product means nothing if no one can tell it's differentBuyers Want Freedom, Agents Want Help• Gen Z wants a home they can paint and own, not just a good deal• Agents are tired, anxious, and open to new kinds of partnerships

Got feedback about this episode? Send Carolyn a text This episode of Inspired Soles features 28-year-old Daniel Heschuk — a highly accomplished and versatile runner who thrives across road, trail, and mountain terrain. Born and raised in Neepawa, Manitoba, Daniel competed for five years at the University of Manitoba in cross country, indoor and outdoor ... more »

The guys (@GamblingPodcast) give out their best bets for College Baseball World Series predictions in this podcast episode. Additionally they discuss their favorite best bets for the UFL Championship Picks with Colby Dant (@TheColbyD) from the UFL Gambling Podcast. They also discuss flying Zebras and Coach O.Go here for free college baseball picks - http://sportsgamblingpodcast.com/college-baseball-picks/Podcast Chapters00:00 Introduction01:09 US Open Golf Bets01:56 College Baseball World Series Preview02:05 Guest Introduction: Omaha Benik02:41 College Baseball Betting Insights13:19 Murray State's Journey15:20 LSU vs Arkansas Matchup19:33 Futures and Jello Shots32:20 Building Your Own Models and Free Picks33:25 Coach O's Viral Moment37:56 Runaway Zebra in Tennessee40:51 UFL Championship Game Preview52:58 Locking in Bets and Final Thoughts Exclusive SGPN Bonuses And Linkshttp://linktr.ee/sportsgamblingpodcastWatch The Sports Gambling Podcast YouTube - https://www.youtube.com/sportsgamblingpodcast Follow The Sports Gambling Podcast X/Twitter - https://x.com/GamblingPodcastInstagram - https://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@gamblingpodcastFacebook - http://www.facebook.com/sportsgamblingpodcastFollow The Sports Gambling Podcast HostsSean Green - http://www.twitter.com/seantgreenRyan Kramer - http://www.twitter.com/kramercentricGambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

The guys (@GamblingPodcast) give out their best bets for College Baseball World Series predictions in this podcast episode. Additionally they discuss their favorite best bets for the UFL Championship Picks with Colby Dant (@TheColbyD) from the UFL Gambling Podcast. They also discuss flying Zebras and Coach O.Go here for free college baseball picks - http://sportsgamblingpodcast.com/college-baseball-picks/Podcast Chapters00:00 Introduction01:09 US Open Golf Bets01:56 College Baseball World Series Preview02:05 Guest Introduction: Omaha Benik02:41 College Baseball Betting Insights13:19 Murray State's Journey15:20 LSU vs Arkansas Matchup19:33 Futures and Jello Shots32:20 Building Your Own Models and Free Picks33:25 Coach O's Viral Moment37:56 Runaway Zebra in Tennessee40:51 UFL Championship Game Preview52:58 Locking in Bets and Final Thoughts Exclusive SGPN Bonuses And Linkshttp://linktr.ee/sportsgamblingpodcastFollow The Sports Gambling Podcast X/Twitter - https://x.com/GamblingPodcastInstagram - https://www.instagram.com/sportsgamblingpodcastTikTok - https://www.tiktok.com/@gamblingpodcastFacebook - http://www.facebook.com/sportsgamblingpodcastFollow The Sports Gambling Podcast HostsSean Green - http://www.twitter.com/seantgreenRyan Kramer - http://www.twitter.com/kramercentricGambling problem? Call 1-800-GAMBLER CO, DC, IL, IN, LA, MD, MS, NJ, OH, PA, TN, VA, WV, WY Call 877-8-HOPENY or text HOPENY (467369) (NY) Call 1-800-327-5050 (MA)21+ to wager. Please Gamble Responsibly. Call 1-800-NEXT-STEP (AZ), 1-800-522-4700 (KS, NV), 1-800 BETS-OFF (IA), 1-800-270-7117 for confidential help (MI)

Tune into "Drill of the Day Podcast," your ultimate daily resource for unlocking next-level basketball skills and coaching strategies. Each episode delivers a fresh, actionable basketball drill designed to sharpen fundamentals, enhance game-specific movements, and boost player development for athletes of all ages. Whether you're a coach seeking innovative practice ideas, a player hungry to elevate your game, or a parent looking to support your young athlete, our expertly curated drills cover everything from shooting and dribbling to defense and agility. Stop searching for stale routines and start mastering the court with our "Drill of the Day"—subscribe now and transform your training, one powerful drill at a time! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Brant talks about the unnecessary weight of anger and anxiety so many of us carry—and shows how following Jesus offers us a much lighter way to live. He shares practical ways to become the kind of person who forgives in real time—yes, even in traffic and connects this to anxiety, too, showing how humans hold onto fear longer than any animal (baby zebras don't get ulcers). The life Jesus offers really is better, and we can live it now. Follow along with this session's notes/slides!